Hongmin Lu, PHD

CONTACT

Lead Sponsor

Grit Biotechnology

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

•1\. Voluntarily join the study, signed informed consent form，willing and able to comply with the study protocol;
•2\. Age 18 to 70 years old;
•3\. Queue 1: Late stage non-small cell lung cancer without driver genes that have failed first-line systemic treatment;Queue 2: Small cell lung cancer with first-line systemic treatment failure;
•4\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
•5\. Expected survival time of ≥ 12 weeks;
•6\. Good function of vital organs;
•7\. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;
•8\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.

•1.Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry;
•2.Known mental illness, alcoholism, drug use or substance abuse;
•3.Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion;
•4.Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study;
•5.The investigators determine that other conditions that make the patient not suitable for enrollment.